Anna Berkenblit, Chief Scientific and Medical Officer at Pancreatic Cancer Action Network, shared a post on LinkedIn:
“Revolution Medicines’ daraxonrasib is featured in Nature Medicine’s ‘Eleven clinical trials that will shape medicine in 2026’ Year in Review, and I’m thrilled about the recognition of this important work.
RevMed’s RASolute 302 phase 3 trial tests daraxonrasib in patients with pancreatic cancer and has the potential to positively impact patient outcomes and open the door to more RAS-targeted strategies.”
More posts featuring Anna Berkenblit.